ZEPP HEALTH CORPORATION (ZEPP)

Zepp Health Corp (ZEPP) reports a 33.8% increase in revenue and narrows operating losses, driven by successful product launches and strategic partnerships.

Zepp Health Corporation provided earnings guidance for second quarter of 2026. For the second quarter of 2026, the Company's management currently expects net revenues to be between USD 63.0 million...

According to ZEPP">InvestingPro analysis, the stock appears undervalued at current levels, placing it among companies on the most undervalued stocks list. Following the earnings announcement, Zepp Health’s stock rose by 3.55% in aftermarket trading, reaching $6.41.

Ladies and gentlemen, thank you for standing by for Zepp Health's fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen only mode. Today's conference call is being recorded. I will now turn the call over to your host, Ms.

Zepp Health’s Q1 2026 revenue rose 33.8% to US$51.5M with 37.7% gross margin, but net loss was US$19.6M. Cash reached US$103.2M and Q2 revenue is guided to US$63–68M.